Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilteritinib Maintenance Post-HCT in FLT3/ITD AML
NCT02997202Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2017
- Primary completion
- Jan 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 16
01
Overview
A Phase 3 trial of gilteritinib in acute myeloid leukemia (AML), sponsored by Astellas Pharma. Started Aug 2017; status: completed.
02
Drugs
gilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02997202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02997202.